The number of companies with approved products and measurable revenues in the field of cell therapy and tissue engineering has exceeded the expectation of many (though not all) in the industry. Markets such as cell/tissue are often characterized by overestimated evaluations of commercial potential and underestimated consideration of the actual challenges. Indeed many technology challenges [...]
Tissue engineering involves taking either autologous, allogeneic or xenogeneic cells and redirecting those cells to carry out fundamental processes. Often the researcher will use a biomaterial matrix and seed the cells into this matrix. The redirection may take the form of stimulating the cells to become stem cells or precursor cells, or it may mean [...]
Publishing a new report in December 2009: Tissue Engineering, Cell Therapy and Transplantation: Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018. This report examines the status of technologies, applications and markets for tissue engineering, cell therapy and tissue/cell transplantation. The report reviews therapeutic tissue engineering, tissue reconstruction, cell therapies, tissue/organ [...]
Researchers at the Salk Intitute for Biological Studies have demonstrated that a technology to correct the genetic defect in human disease and induce cell differentiation at the site of the manifested disease is feasible, an achievement demonstrated previously only in mice. In the May 31, 2009, edition of Nature, Salk reseachers published their findings [...]
Contact:
